Triage of HPV-positive women in cervical cancer screening

The Lancet Oncology

Volumn 14, Issue 2, 2013, Pages 107-109

  Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; PROTEIN P16;

CANCER SCREENING; COLPOSCOPY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LETTER; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS;

EID: 84873087762     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70568-5     Document Type: Letter

References (9)

1. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011, 103:368-383.
2. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2012, published online Dec 21. http://dx.doi.org/10.1016/S1470-2045(12)70529-6.
3. Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011, 20:1398-1409.
4. Cuschieri K, Wentzensen N Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008, 17:2536-2545.
5. Wentzensen N, Wacholder S. From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discovery (in press).
6. Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011, 12:880-890.
7. Carozzi F, Confortini M, Dalla PP, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008, 9:937-945.
8. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012, 62:147-172.
9. Wentzensen N, Schwartz L, Zuna RE, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 2012, 18:4154-4162.